Verastem Reports Strong Long-Term Efficacy and Safety Data for Approved LGSOC Therapy
Summary
Verastem filed an 8-K with an updated corporate presentation, revealing new long-term clinical data for its approved LGSOC therapy, AVMAPKI FAKZYNJA CO-PACK, showing durable efficacy and a favorable safety profile.
Key Events
-
New Long-Term Clinical Data Released
The corporate presentation includes new long-term efficacy and safety data from the RAMP 201 study for AVMAPKI FAKZYNJA CO-PACK in recurrent LGSOC.
-
Durable Responses Confirmed
Over half of responders (56%) maintained their response at 24 months, with median Duration of Response (mDoR) for KRAS mutant patients remaining at 31.1 months and median Progression-Free Survival (mPFS) at 19.6 months.
-
Favorable Safety Profile Maintained
The discontinuation rate due to adverse events remained low at 12% even with extensive follow-up, indicating good tolerability.
-
Q1 2026 Financials and Outlook
The presentation also reiterated Q1 2026 net product revenue of $18.7 million and projected a cash runway into 2027, with the AVMAPKI FAKZYNJA CO-PACK franchise expected to be self-sustaining in 2H 2026.
Analysis
This 8-K filing, accompanying the Q1 2026 earnings, provides a significant update on the long-term efficacy and safety of Verastem's approved drug, AVMAPKI FAKZYNJA CO-PACK, for recurrent Low-Grade Serous Ovarian Cancer (LGSOC). The new data from the RAMP 201 study demonstrates durable responses and a low discontinuation rate, reinforcing the drug's commercial potential and strengthening the investment thesis for its key product. This positive clinical update, alongside the Q1 financial results, provides a clearer picture of the company's operational and financial health.
At the time of this filing, VSTM was trading at $5.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497.2M. The 52-week trading range was $4.01 to $11.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.